SAGE Therapeutics (SAGE) Misses Q3 EPS by 36c, Reports $1.8B of Cash on Hand
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
November 2, 2021 6:30 AM EDTNDA submission for zuranolone for the treatment of MDD expected to be filed in the second half of 2022, with rolling submission planned to begin in early 2022
CORAL Study primary endpoint updated, in line with goal of study to demonstrate rapid reduction in depressive symptoms and benefits throughout treatment period when co-initiated with standard antidepressants
Continued pipeline progress demonstrated across brain health franchises, with plans to initiate three Phase 2 studies across SAGE-324 and SAGE-718 programs
Conference call today at 8:00 a.m. ET
CAMBRIDGE,... More
